Journal article
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces
Abstract
INTRODUCTION: Treatment using abiraterone acetate plus prednisone, enzalutamide, cabazitaxel, and radium-223 (Ra-223) improves overall survival (OS) and quality of life for patients with metastatic castrate-resistant prostate cancer (mCRPC). Despite their proven benefits, access to these therapies is not equal across Canada.
METHODS: We describe provincial differences in access to approved mCRPC therapies. Data sources include the pan-Canadian …
Authors
Woon DTS; Chandrasekar T; Aaron L; Basappa NS; Chi KN; Conter HJ; Gotto G; Hotte SJ; Malone S; Saad F
Journal
Canadian Urological Association Journal, Vol. 12, No. 8, pp. 328–336
Publisher
Canadian Urological Association Journal
Publication Date
October 2018
DOI
10.5489/cuaj.5378
ISSN
1911-6470